心力衰竭的经济学
The economics of cardiac failure.
作者信息
Kleber F X
机构信息
Med. Klinik u. Poliklinik I, Humboldt-Universität, Berlin, Germany.
出版信息
J R Soc Med. 1996 Jan;89(1):9-12. doi: 10.1177/014107689608900104.
Abstract
Quality assurance and inclusion of prospective evaluation of costs of treatment in phase 3 and 4 pharmaceutical trials are becoming increasingly important. Not only high technology applications have to be investigated, but also relatively cheap but very common strategies for diagnostic work up and therapy. This may yield major savings. We are at the beginning of an era in which waste of resources may be reduced by scientific analysis with improvement in patient care and teaching achieved as a result.
摘要
质量保证以及将治疗成本的前瞻性评估纳入3期和4期药物试验正变得越来越重要。不仅要研究高科技应用，还要研究诊断检查和治疗中相对便宜但非常常见的策略。这可能会带来大幅节省。我们正处于一个时代的开端，通过科学分析可以减少资源浪费，从而改善患者护理并实现教学目标。
相似文献
1
The economics of cardiac failure.心力衰竭的经济学
J R Soc Med. 1996 Jan;89(1):9-12. doi: 10.1177/014107689608900104.
2
Cost effectiveness of carvedilol for heart failure.卡维地洛治疗心力衰竭的成本效益
Am J Cardiol. 1999 Mar 15;83(6):890-6. doi: 10.1016/s0002-9149(98)01066-2.
3
Clinical and economic impact of nesiritide.
Am J Health Syst Pharm. 2003 Aug 15;60 Suppl 4:S21-6. doi: 10.1093/ajhp/60.suppl_4.S21.
4
Sodium Nitrite-Mediated Cardioprotection in Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Cost-Effectiveness Analysis.亚硝酸钠介导的 ST 段抬高型心肌梗死患者经皮冠状动脉介入治疗中的心脏保护作用：成本效果分析。
J Cardiovasc Pharmacol Ther. 2019 Mar;24(2):113-119. doi: 10.1177/1074248418784940. Epub 2018 Aug 6.
5
Nesiritide utilization evaluation in a university teaching hospital.
J Clin Pharm Ther. 2005 Oct;30(5):447-53. doi: 10.1111/j.1365-2710.2005.00665.x.
6
New technologies and potential cost savings related to morbidity and mortality reduction in Class III/IV heart failure patients in Canada.加拿大用于降低III/IV级心力衰竭患者发病率和死亡率的新技术及潜在成本节约。
Int J Cardiol. 2003 Mar;88(1):33-41. doi: 10.1016/s0167-5273(02)00378-9.
7
[Economic significance of heart failure. An overview of costs and economics of therapy].
Herz. 2000 Aug;25(5):538-46. doi: 10.1007/pl00001966.
8
Cost-effective management of heart failure.
Clin Cardiol. 1996 Mar;19(3):240-2. doi: 10.1002/clc.4960190319.
9
Clinical and economic impact of multipoint left ventricular pacing: A comparative analysis from the Italian registry on multipoint pacing in cardiac resynchronization therapy (IRON-MPP).多点左心室起搏的临床和经济影响：来自心脏再同步治疗多点起搏意大利注册研究（IRON-MPP）的比较分析。
J Cardiovasc Electrophysiol. 2020 May;31(5):1166-1174. doi: 10.1111/jce.14433. Epub 2020 Mar 12.
10
Health economics of cardiac resynchronization therapy.
Br J Hosp Med (Lond). 2017 Oct 2;78(10):594. doi: 10.12968/hmed.2017.78.10.594.
引用本文的文献
1
The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.微量蛋白检测的经济学。群多普利对心肌梗死后左心室功能不全患者的成本效益分析。
Pharmacoeconomics. 1998 Jul;14(1):49-58. doi: 10.2165/00019053-199814010-00005.
2
Culture and medicine.
J R Soc Med. 1998 Mar;91(3):118-26. doi: 10.1177/014107689809100302.
本文引用的文献
1
Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model.
Pharmacoeconomics. 1993 May;3(5):387-97. doi: 10.2165/00019053-199303050-00006.
2
A medication discharge planning program: measuring the effect on readmissions.
Clin Nurs Res. 1993 Feb;2(1):41-53. doi: 10.1177/105477389300200105.
3
Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group.评估地高辛撤药对轻至中度慢性充血性心力衰竭患者影响的随机研究：PROVED试验结果。PROVED研究组
J Am Coll Cardiol. 1993 Oct;22(4):955-62. doi: 10.1016/0735-1097(93)90403-n.
4
The incidence and prevalence of congestive heart failure in Rochester, Minnesota.明尼苏达州罗切斯特市充血性心力衰竭的发病率和患病率。
Mayo Clin Proc. 1993 Dec;68(12):1143-50. doi: 10.1016/s0025-6196(12)60063-9.
5
[Increase in the number of admissions due to heart failure in Dutch hospitals in the period 1980-1992].[1980年至1992年期间荷兰医院因心力衰竭入院人数的增加]
Ned Tijdschr Geneeskd. 1994 Apr 23;138(17):866-71.
6
Improving patient care: consequences for resource allocation.
Cardiology. 1994;84(6):420-6. doi: 10.1159/000176434.
7
The cost:benefit ratio of acute intervention for myocardial infarction: results of a prospective, matched pair analysis.
Am Heart J. 1989 Nov;118(5 Pt 1):878-82. doi: 10.1016/0002-8703(89)90217-2.
8
Hospital costs, resource characteristics, and the dynamics of death for patients with a primary diagnosis of congestive heart failure.
N Y State J Med. 1989 Feb;89(2):60-3.
9
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.依那普利与肼屈嗪-硝酸异山梨酯治疗慢性充血性心力衰竭的比较。
N Engl J Med. 1991 Aug 1;325(5):303-10. doi: 10.1056/NEJM199108013250502.
10
Efficient diagnosis of common complaints: a comparative study in the United States and England.
J Fam Pract. 1991 Jul;33(1):41-6.
Zotero 插件